Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
Vogt
Thomas
T
Department of Dermatology, University of Regensburg, Germany. thomas.vogt@klinik.uni-regensburg.de
Coras
Brigitte
B
Hafner
Christian
C
Landthaler
Michael
M
Reichle
Albrecht
A
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D000069287:Capecitabine; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008178:Lupus Erythematosus, Cutaneous / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000188:drug therapy*; D000077205:Pioglitazone; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D045162:Thiazolidinediones / Q000008:administration & dosage*
D020533:Angiogenesis Inhibitors; D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D045162:Thiazolidinediones; D003841:Deoxycytidine; D000069287:Capecitabine; D003520:Cyclophosphamide; C003726:trofosfamide; D005472:Fluorouracil; D000077205:Pioglitazone